Progyny said revenue increased by $27.9 million, or 9%, and gross profit increased by $10.9 million, or 15%, for the three months ended September 30, 2026 compared with September 30, 2025.
PGNY · Progyny, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Progyny reported record third-quarter revenue and profitability, a selling season yielding record 1.3 million new covered lives and over 85 clients, near 100% retention, and raised full-year 2026 guidance.
Progyny reported record third-quarter revenue of $341.3 million, up 8.9%, net income of $26.3 million and Adjusted EBITDA of $58.4 million. It raised full-year 2026 revenue guidance to $1.365 billion to $1.385 billion.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Progyny delivered record quarterly revenue, gross profit, and adjusted EBITDA with 180 bps of gross margin expansion while reiterating full-year 2026 revenue guidance of $1.36–$1.385 billion and Q3 guidance that reflects a slightly more pronounced summer seasonality. The company repurchased an additional 2 million shares under a new $200 million program and reported strong selling-season momentum with early commitments pacing meaningfully ahead of last year.
- + Reported record quarterly revenue of $350.5M with 5.3% reported growth (11% ex-large former client) and record adjusted EBITDA of $62.1M.
- + Gross margin expanded 180 basis points year-over-year to 25.5%, reflecting care-management efficiencies and lower stock-based compensation.
- + Selling-season momentum accelerated, with early commitments pacing meaningfully ahead of last year and retention risk largely removed earlier than usual.
- + Reiterated full-year 2026 revenue guidance of $1.360–$1.385B (9.7–11.7% ex-large former client) and adjusted EBITDA of $233–$240M.
- − Q3 guidance of $335–$345M revenue and $56–$59M adjusted EBITDA reflects slightly more pronounced summer seasonality than in prior years.
- − CapEx rose to $6.2M in Q2, a $1M increase year-over-year, as the company continues a multi-year platform investment cycle.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Earnings Per Diluted Share non-GAAP | $1.04 | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $62.1M | Second Quarter 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income 28.05M
+1.62M Depreciation and amortization
+20.48M Stock-based compensation expense
-1.13M Interest and other income, net
+13.09M Provision for income taxes
= Adjusted EBITDA 62.1M
|
|||
| Adjusted EBITDA Margin non-GAAP | 17.7% | Second Quarter 2026 | — |
| ART Cycles per Unique Female Utilizer | 0.51 | Three months ended June 30, 2026 | — |
| Assisted Reproductive Treatment (ART) Cycles | 32,645 | Six Months Ended June 30, 2026 | — |
| Average Members | 7,176,000 | Six Months Ended June 30, 2026 | — |
| Female Utilization | 0.49% | 2Q 2026 | — |
| fertility and family building clients | 604 | As of June 30, 2026 | — |
| Utilization - All Members | 0.85% | Six Months Ended June 30, 2026 | — |
| Utilization - Female Only | 0.71% | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PGNY
this stock
Progyny, Inc.
|
$2.66B | +40.8% | +10.4% | 33.2 | 6.5% |
|
UNH
Unitedhealth Group Inc
|
$313.53B | +6.0% | +11.8% | 20.0 | 1.6% |
|
CVS
CVS HEALTH Corp
|
$104.09B | +2.5% | +7.8% | 9.5 | 1.4% |
|
ELV
Elevance Health, Inc.
|
$86.60B | +14.3% | +12.5% | 17.0 | 2.1% |
|
CI
Cigna Group
|
$75.20B | +3.7% | +11.2% | 12.6 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 23
Progyny said revenue increased by $27.9 million, or 9%, and gross profit increased by $10.9 million, or 15%, for the three months ended September 30, 2026 compared with September 30, 2025.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PGNY | -0.9% | +27.1% | +41.5% | +23.9% | +40.8% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +3.0% | +32.7% | +44.9% | +27.3% | +33.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.